Shares touched a high of $2.02 in morning trading, up from Wednesday’s closing price of $1.85.

The complaints charge Apple with infringing on 10 of Unwired Planet’s patents, and charge Google with infringing on 10 different patents, according to a September 20 press release. The 20 patents are related to smart mobile devices, cloud computing, digital content stores, push notification technologies and location-based services including mapping and advertising, the press release stated.

“Apple and Google generate substantial revenues from devices and services that rely on the intellectual property that Unwired Planet developed and patented over the last 15 years,” said Unwired Planet’s CEO Mike Mulica in the September 20 press release. “They should compensate us for the use of our patented technologies, which are foundational to mobility.”

The complaints were filed in Nevada, which was chosen as “one of 14 districts across the United States as a pilot patent district,” and has developed “specialized procedures to handle complex patent cases,” Mulica said. “As a result, we believe the Nevada district will be an ideal venue to resolve this matter with efficiency and expertise.”

Unwired Planet has about 200 U.S. and foreign patents and roughly 75 pending applications, Fores reported.

Shares of UPIP are down about 19 percent over the past three months.

Groupon shares touched a high of $5.17 in morning trading on Wednesday, up from Tuesday’s closing price of $4.69.

According to a September 19 press release, Groupon Payments allows any merchant that runs a deal with Groupon in the U.S. to accept payments “at the lowest rates in today’s market place.” The press release stated that MasterCard, Visa and Discover transactions will cost merchants 1.8 percent and a 15 cent transaction fee, and American Express transactions will cost merchants 3 percent plus a 15 percent transaction fee.

“Our goal is to provide merchants with the most affordable and powerful tools to run and grow their businesses,” said Mihir Shah, VP Mobile and Merchant Products at Groupon in the September 19 press release. “With groundbreaking pricing and service, Groupon Payments does just that.”

The technology was initially tested int he San Francisco Bay area. And although the rates may seem attractive, Groupon faces stiff competition from EBay’s PayPal unit and Square, a service founded by Jack Dorsey (co-founder of Twitter).

Despite the competition, Groupon’s rates are somewhat lower than competitors’ rates. Square charges 2.75 percent per swipe, or $275 per month. PayPal charges 2.7 percent, the Associated Press reported.

Shares of Groupon are down about 50 percent over the past three months.

MTSL hit an intraday high of $2.84 per share on Friday, up from Thursday’s closing price of $1.60.

Revenue for the second quarter was $3.3 million, up from $3 million in the same period a year ago. Operating income from the quarter skyrocketed to $517,000, a 170 percent improvement over operating profit of $191,000 for the same quarter a year earlier. Net income improved to $460,000, or 10 cents per share, up from $229,000 or 5 cents per share in the second quarter of 2011.

“Our second quarter results represent continued improvements in our financial results and indicators as a result of our efforts to develop our Telecom Expense Management opportunities through partners, new customer acquisitions and expanding our existing customer base,” said Eytan Bar, CEO of MTS in an August 16 press release. ”In addition, our company’s Billing and Mobile Virtual Network Operator (MVNO) activity as a managed service has grown and we were able to sign an additional managed service agreement with a new MVNO in the U.S. and we see other opportunities in this market. We are looking forward to improving both our top and bottom line performance.”

Shares of MTSL are up more than 50 percent over the past three months.

Shares climbed as high as $4.89 on Thursday, up from Wednesday’s closing price of $3.18.

The company reported 2011 revenue of $226.7 million, up 28.9 percent from the previous year. The growth was driven by the company’s sales expansion in the China domestic market for its Deer branded product lines coupled with Deer Consumer Products’ ability to raise the average selling prices of its products, a March 29 press release stated.

Net income for 2011 increased 31 percent to $39.8 million, or $1.18 per share, over the same period last year.

The company also reaffirmed its 2012 financial guidance, and stated that it expects 2012 revenue guidance of between $270 million and $290 million, and net income of between $45 million and $47 million.

Deer’s product mix includes housewares and appliances such as blenders, choppers, food processors, and microwave ovens.

“Deer currently has access to approximately 4,000 retail locations across China and has developed a well-recognized brand by working with various retail channels,” said Deer Consumer Products’ Chairman and CEO Bill He in a March 29 press release. ”We believe China remains the world’s largest and fastest growing consumer retail market and has strong domestic demand for small household appliances. There are approximately 35,000 retail locations across China that Deer could potentially penetrate. Deer has significant growth potential in China.”

Shares of DEER are down roughly 39 percent over the past 12 months, according to historical data provided by Yahoo Finance.

According to data provided by Yahoo Finance, shares of AMLN touched a high of $23.50 on Wednesday, up from Tuesday’s closing price of $15.39.

Reuters reported that Amylin has been considered a possible takeover target for quite some time. Spokeswomen for Bristol-Myers and Amylin refused to comment, Reuters reported.

“Bristol as an acquirer makes sense,” Robyn Karnauskas, an analyst with Deutsche Bank in New York, wrote in a note to clients today, Bloomberg reported. “Amylin could be worth up to $31 a share based on expense synergies. However, Bristol is financially disciplined.”

There have been 16 acquisitions more than $1 billion of biotech companies in Amylin’s peer group in the past five years, according to data compiled by Bloomberg. The average disclosed size was $8 billion, with an average premium of 35 percent, the Bloomberg data show.

Chelsea Therapeutics shares touched a high of $4.09 on Friday, up from Thursday’s closing price of $2.41.

“We believe our clinical data demonstrates the significant symptomatic benefit of Northera treatment across a broad range of Neurogenic OH symptoms,” said Chelsea Therapeutics’ CEO Dr. Simon Pedder in a statement. “Since no other treatment has been proven to alleviate the symptoms of neurogenic OH or improve patients’ ability to carry out activities of daily living, we continue to believe Northera could fill this unmet need for patients with Parkinson’s disease, MSA, PAF and other neurologic diseases. We are pleased by today’s panel vote and we look forward to continuing to work with the FDA in advance of the March 28, 2012 PDUFA action date.”

Northera is the lead investigational agent in Chelsea’s pipeline, and has has been studied in two Phase III clinical trials for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure — a group of diseases that includes Parkinson’s disease, multiple system atrophy (MSA) and pure autonomic failure (PAF). Droxidopa is a synthetic catecholamine that is directly converted to norepinephrine (NE) via decarboxylation, resulting in increased levels of NE in the nervous system, both centrally and peripherally.

Chlesea Therapeutics submitted a New Drug Application (NDA) for Northera in September 2011. The drug was previously granted Orphan Drug Designation, which is granted by the FDA to treatments for rare diseases and disorders.

The Facetones app is integrated with Facebook and generates an automatic, visually exciting slideshow of photos displaying your friend’s face and other social content each time you communicate with that friend using your mobile device.  With Vringo’s latest version of Facetones , the application is now fully optimized for Nokia’s Symbian^3 operating system.

The free ad supported app has been a viral hit for Vringo and is closing in on one million downloads. VRNG monetizes this app using Google’s Admob mobile advertising service and it is currently generating 800,000- 900,000 ad impressions per day.

About Vringo

Vringo (AMEX: VRNG) is a provider of software platforms for mobile social and video applications. With its award-winning video ringtone application and other mobile software platforms – including Facetones™, Video Remix and Fan Loyalty – Vringo transforms the basic act of making and receiving mobile phone calls into a highly visual, social experience. Vringo’s video ringtone service enables users to create or take video, images and slideshows from virtually anywhere and turn it into their visual call signature. In a first for the mobile industry, Vringo has introduced its patented VringForward technology, which allows users to share video clips with friends with a simple call.  Vringo’s Facetones™ application creates an automated video slideshow using friends’ photos from social media web sites, which is played each time a user communicates with a friend using a mobile device. Vringo’s Video ReMix application, in partnership with music artists and brands, allows users to create their own music video by tapping on a Smartphone or tablet.  Lastly, Fan Loyalty is a platform that lets users interact, vote and communicate with contestants in reality TV series that it partners with, as well as downloading and setting clips from such shows as video ringtones. Vringo’s video ringtone application has been heralded by The New York Times as “the next big thing in ringtones” and USA Today said it has “to be seen to be believed.” For more information, visit: www.vringo.com

The growth of Caterpiller is a positive indicator in the strength of the global economy and in construction spending in the United States. Caterpillar credits the incredible growth to many of its customers replacing aging equipment and rapid growth in developing parts of the world.

“Our strategy is squarely focused on customers, and in 2011 our employees, suppliers and dealers delivered. We improved product quality, invested significantly in manufacturing capacity and product  development, and improved our market position.” said Caterpillar Chairman and Chief Executive Officer Doug Oberhelman.

About Caterpillar Inc. (NYSE: CAT)

Caterpillar Inc. is a corporation which designs, manufactures, markets and sells machinery and engines and sells financial products and insurance to customers via a worldwide dealer network. Caterpillar is the world’s largest manufacturer of construction and mining equipment, diesel and natural gas engines and industrial gas turbines.  With more than US$70 billion in assets, Caterpillar was ranked number one in its industry and number 44 overall in the 2009 Fortune 500. Caterpillar stock is a component of the Dow Jones Industrial Average.

The $26 cash offer for Alpharetta-based Inhibitex represents a 163 premium to Friday’s closing price of $9.87.

“The acquisition of Inhibitex builds on Bristol-Myers Squibb’s long history of discovering, developing and delivering innovative new medicines in virology and enriches our portfolio of investigational medicines for hepatitis C,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb in a January 7 press release. “There is significant unmet medical need in hepatitis C. This acquisition represents an important investment in the long-term growth of the company.”

Inhibitex’s lead hepatitis C asset  is INX-189, an oral nucleotide polymerase (NS5B) inhibitor in Phase II development that has exhibited potent antiviral activity, a high barrier to resistance and pan-genotypic coverage.

“The addition of Inhibitex’s nucleotide polymerase inhibitor to our own promising portfolio, which includes other direct-acting antivirals, brings additional options to develop all-oral regimens with better cure rates, shorter duration of therapy and lower toxicity than the current standard of care,” said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, R&D, Bristol-Myers Squibb said in a statement.

The transaction is expected to be dilutive to earnings for Bristol-Myers Squibb through 2016, with an expected impact on earnings per share of approximately $0.04 in 2012 and approximately $0.05 in 2013, the January 7 press release stated.

About Inhibitex, Inc. (Nasdaq: INHX)

Inhibitex, Inc. is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s clinical-stage pipeline includes two Phase 2 development programs for which it has retained all future rights: INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic HCV infections, and FV-100, a nucleoside analogue in development for the treatment of shingles-associated pain. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM^® protein platform to Pfizer for the development of a staphylococcal vaccine, which is currently being evaluated in a Phase 1/2 clinical trial.

For additional information about the Company, please visit www.inhibitex.com.

On Tuesday, the Tel Aviv-based RiT Technologies announced that it appointed Peter Leonard to become its Country Sales Manager for South Africa. According to a December 6 press release, RiT’s has built momentum in the region over the past year, beginning with sales to Botswana Teclecommunications Corp. and Vodafone Ghana, and followed by the signing of distribution/marketing agreements with Kenya’s Adwest communications, Mart Network Solutions/Giganet Networking Solutions and Adcare.

RiT Technologies’ president and CEO, Eran Ayzik commented that Africa is a “land in transformation, and a key enabler of change is the ongoing overhaul of its communications and IT networks.”

The company has also increased its presence in China, opening a new office in Shanghai several months ago as part of its strategic focus on the Chinese market.

“The establishment of our second office in Chinademonstrates the success of our strategy to build our business in this rapidly-growing market with high potential for IIM sales,” Ayzik said in a September 13 press release.  ”Our unique approach to the market, including our partnership with superbly qualified, well-connected integrators and the offering of customized solutions, has started to pay off, and we believe thatChina will continue growing in importance as a driver of our future sales.”

For the third quarter ended September 30, RiT Technologies reported revenue of $3.7 million, a 38 percent increase over revenue of $2.7 million in the same period a year ago, and a 7 percent sequential increase over the second quarter. The company’s third quarter net loss increased 1 percent to $854,000 or 19 cents per share, compared to a net loss of $843,000 or 26 cents per share for the third quarter of 2010.

“Our third quarter results reflect continued strong momentum in the areas of product development, partnership building and marketing & sales, all of which are creating a solid platform for future growth,” Ayzik said in an October 26 press release. ” Our efforts to broaden our sales and marketing activities are raising RiT’s exposure in emerging markets and enabling us to better serve our customers. This was highlighted during the quarter by our opening of a second sales office in China. And we intend to duplicate this effort in other high growth, emerging regions.”Parallel to our marketing activities, we continue to develop our product portfolio, improve our supply chain and deepen our strategic partnerships in order to well-position the Company for further growth.”

Shares of RITT are down about 6 percent in the past three months.